GCG and obesity due to melanocortin 4 receptor deficiency: However, with the rise of the incretin-based pharmacotherapies, including dual and triple incretin agonists and their associated remarkable weight-loss effects (almost now equivalent to some forms of bariatric surgery) [14,15], it seems likely that future treatment algorithms for obesity will place less emphasis on the relative positioning of each management option generally, but rather focus on the needs of individuals.